sponsored
PatientsVille.com Logo

PatientsVille

C-reactive Protein Increased Medical Research Studies

Up-to-date List of C-reactive Protein Increased Medical Research Studies

What Research is Being Done?

A clinical study involves research using human volunteers (also called participants) that is intended to add to medical knowledge. There are two main types of clinical studies: clinical trials (also called interventional studies) and observational studies. Following list includes both interventional and observational studies.

Latest C-reactive Protein Increased Medical Research Studies

Rank Status Study
1 Unknown  Study of Talactoferrin Oral Solution for Nosocomial Infection in Preterm Infants
Condition: Nosocomial Infections
Interventions: Drug: Talactoferrin;   Drug: Placebo
Outcome Measures: Reduction in incidence of Late-Onset Infection defined by positive cultures and elevated C-reactive protein (CRP);   "NEC Scares", the "Neonatal Sepsis Syndrome";   Length of stay: The number of days of hospitalization from the date of birth until the day of discharge from the NICU;   Mortality during hospitalization
2 Recruiting Effects of Rosuvastatin on the Immune System in Healthy Volunteers With Normal Cholesterol
Condition: Healthy Volunteers
Intervention:
Outcome Measures: To elucidate the effects of a four week course of statins on the immune system in healthy volunteers with normal cholesterol with or without elevated C-reactive protein.;   To describe the effects of statins on platelet activity and coagulation during thrombus formation.
3 Unknown  Pravastatin Therapy in Patients With Active Crohn's Disease: A Pilot Study
Condition: Crohn's Disease
Intervention: Drug: Pravastatin
Outcome Measure: Primary outcome will be clinical benefit which will be defined as a decrease in HBI, fecal lactoferrin, CRP and/or ESR at 6 weeks compared with baseline values
4 Unknown  Surveillance of Hospitalised Pneumonia and Bacterial Meningitis in Tône District, Togo, 2010-2013
Conditions: Pneumonia, Bacterial;   Pneumonia, Viral;   Meningitis, Bacterial
Intervention:
Outcome Measures: Incidence of pneumococcal pneumonia requiring hospitalisation, confirmed by blood culture or PCR analysis of blood;   Incidence of pneumococcal meningitis, confirmed by culture or PCR on cerebro-spinal fluid;   Incidence of radiologically confirmed pneumonia requiring hospitalisation;   Incidence of suspected pneumonia requiring hospitalisation with elevated C-reactive protein serum concentration (<40mg/l);   Incidence of suspected pneumonia requiring hospitalisation with reduced oxygen saturation (<90%);   Incidence of pneumonia of other bacterial or viral etiology requiring hospitalisation;   Incidence of acute meningitis of other bacterial etiology
5 Recruiting Effect of Symptom Management on Inflammation and Survival in Metastatic Lung Cancer
Conditions: Lung Neoplasms;   Carcinoma, Non-Small-Cell Lung
Intervention:
Outcome Measures: Overall Survival;   Percentage of patients who convert from c-reactive protein 'high' (> 10 mg/L) to 'low' (<10 mg/L);   Quality of Life (QOL) indicators per FACT-L score and the following at baseline, 4 months and 10 months groups;   Change in VeriStrat status
6 Unknown  Clinical Impact of Bacteriuria on Chronic Inflammation in Asymptomatic Hemodialysis Patients
Conditions: Inflammation on Dialysis;   Bacteriuria in Hemodialysis Patients
Intervention: Other: Antibiotic treatment
Outcome Measures: Change in serum inflammatory markers (CRP, IL-6);   Cardio-vascular events
7 Unknown  The Rate of C-reactive Protein (CRP) Increase as a Marker for Bacterial Infections in Children
Conditions: Bacterial Infections;   Viral Infection
Intervention:
Outcome Measure:
8 Unknown  CRP-guided Antibiotic Treatment in COPD Exacerbations Admitted to the Hospital
Conditions: COPD;   Exacerbation;   Bronchitis;   Sputum;   C-Reactive Protein
Intervention: Other: CRP-guided antibiotic treatment
Outcome Measures: Number of patients treated with antibiotics during hospital stay;   Time to treatment failure within 30-days;   Length of stay;   Time to next exacerbation;   Symptom scores (VAS-LRTI, George's Respiratory Questionnaire);   Adverse events
9 Recruiting The Performance of an Artificial Pancreas at Home in People With Type 1 Diabetes
Condition: Type 1 Diabetes
Interventions: Device: Closed Loop;   Device: Open Loop
Outcome Measures: Continuous glucose monitoring (CGM) time spent in target glycaemic range (4.0-8.0 mmol/L) overnight (2000h - 0800h) during the ambulatory phase (Phase 2) of the study.;   Continuous glucose monitoring (CGM) time spent in target glycaemic range (4.0-8.0 mmol/L) overnight in clinical trial centre (phase 1 of the study).;   CGM time and area under the curve (AUC) spent above target range (>8.0 mmol/L).;   CGM time spent in hypoglycaemic range (<4.0 mmol/L and <3.0 mmol/L) and number of episodes of symptomatic hypoglycaemia (indicated by glucose sensor and confirmed by meter glucose).;   CGM measures of glycaemic variability (standard deviation and margin of error).;   Number of episodes of blood ketone-positive hyperglycaemia (blood glucose > 15 mmol/L indicated by glucose sensor and confirmed by meter glucose AND blood ketones greater than or equal to 0.6 mmol/L).;   Yellow Springs Instrument (YSI) glucose measurements in target range (4.0-8.0 mmol/L).;   YSI glucose measurements in hypoglycaemic range (<4.0 mmol/L and <3.0 mmol/L).;   YSI glycaemic variability (standard deviation).;   CGM time in glucose target range (4.0-8.0 mmol/L).;   Total insulin delivered (based on pump data);   Total insulin delivered (based on pump data).;   Rates and number of changes in the rate of insulin infusion (based on pump data).;   Closed loop exits (with root cause identified) based on the monitoring by the investigator in real time from a co-located station.;   Closed loop exits (with root cause identified) based on the remote monitoring by the investigator.;   Total basal and total bolus insulin delivered (based on pump data);   Total basal and total bolus insulin delivered (based on pump data).;   Urinary cortisol and catecholamines on 12-hour urine collection.;   Area under the curve for overnight plasma cortisol, growth hormone, glucagon, adrenaline and noradrenaline (based on hourly blood sample collection).;   Plasma metanephrines (based on blood sample collection);   Plasma Cortisol, growth hormone, glucagon, adrenaline , noradrenaline and metanephrines based on blood sample collection.;   Sleep quality includes: total sleep time, sleep onset latency, sleep-efficiency, and wakefulness after sleep onset (WASO), total and average activity counts based on Actigraph data.;   Sleep quality includes: total sleep time, sleep onset latency, sleep-efficiency, and wakefulness after sleep onset (WASO), total and average activity counts based on Actigraph data and the Pittsburgh Sleep Quality Index scores.;   Parameters of Inflammation and Oxidative Stress include: Cell Adhesion Molecules, Myeloperoxidase, Oxidised LDL, hs-CRP (based on blood sample collection) and Urinary isoprostanes.;   Parameters of Inflammation and Oxidative Stress include: Cell Adhesion Molecules, Myeloperoxidase, Oxidised LDL, hs-CRP (C reactive Protein) based on blood sample collection, and Urinary isoprostanes.;   Diabetes Treatment Satisfaction Questionnaire and Semi-Structured Interviews (Questionnaires will generate total scores for treatment satisfaction, fear of hypoglycaemia, diabetes-related distress and hypoglycemia impaired awareness).;   Cognitive Assessment: CogState assessment battery outcome measures will be generated. Each battery test point will record participant response times and accuracy rates for all tasks performed.
10 Unknown  Evaluation of Endocrine and Metabolic Parameters in the New Diagnostic Phenotypes of Polycystic Ovary Syndrome
Condition: Polycystic Ovary Syndrome
Intervention: Procedure: Blood samples, transvaginal ultrasound
Outcome Measure: Serum levels: Total, bioavailable testosterone, Free androgen index. Total, LDL and HDL Cholesterol, Triglycerides, insulinemia, OGTT, HOMA index, Adiponectin, C Reactive Protein. Transvaginal Ultrasound:Number,size of ovary follicles and ovary volume
11 Recruiting Optimising Diagnosis and Antibiotic Prescribing for Acutely Ill Children in Primary Care
Conditions: Sepsis;   Bacteraemia;   Meningitis;   Abscess;   Pneumonia;   Osteomyelitis;   Cellulitis;   Gastro-enteritis With Dehydration;   Complicated Urinary Tract Infection;   Viral Respiratory Infection Complicated With Hypoxia
Interventions: Device: Use of C-reactive protein (CRP) point of care test;   Other: Brief intervention and parent leaflet;   Device: Finger Pulse Oximeter
Outcome Measures: Serious infection;   Immediate antibiotic prescribing rates;   Parental satisfaction;   Parental concern;   Use of other diagnostic tests and medical services (including re-consultation);   Cost-effectiveness;   Impact of the communicator style on the effect of the intervention (interaction)
12 Unknown  Can Advair and Flovent Reduce Systemic Inflammation Related to Chronic Obstructive Pulmonary Disease (COPD)? A Multi-Center Randomized Controlled Trial
Condition: Chronic Obstructive Pulmonary Disease
Interventions: Drug: Advair;   Drug: Flovent
Outcome Measures: Change in serum C-reactive protein levels over 3 months between treatment groups.;   changes in serum interleukin levels; quality of life; FEV1 between treatment groups
13 Unknown  A Randomized Trial of LOVAZA in Pediatric Sickle Cell Disease (SCD)
Conditions: Sickle Cell Disease;   HEMOGLOBIN SS;   Hemoglobin S Beta-0 Thalassemia;   Inflammation;   Quality of Life
Interventions: Dietary Supplement: Omega-3 Fatty Acids: Eicosapentaenoic Acid (EPA) and Docosahexaenoic Acid (DHA);   Other: Placebo Capsules
Outcome Measures: To determine whether supplementation with LOVAZA will exert an anti-inflammatory effect by decreasing levels of the inflammatory biomarker high sensitivity C Reactive Protein (hsCRP) in children and adolescents with Sickle Cell Disease (SCD).;   To determine whether supplementation with LOVAZA will increase health-associated quality of life (QoL) responses as they relate to clinical vasocclusive events (VOC) in children and adolescents with Sickle Cell Disease (SCD).
14 Unknown  C-Reactive Protein (CRP) Gene Variants and Coronary Artery Disease in a Chinese Han Population
Condition: Coronary Artery Disease
Intervention:
Outcome Measure:
15 Recruiting Periodontal Disease as a Risk Indicator for Erectile Dysfunction - A Cross-sectional Study on 100 Patients
Conditions: Erectile Dysfunction;   Periodontitis;   hsCRP
Intervention:
Outcome Measures: IIEF-questionnaire-value;   high sensitive C-reactive protein;   severity of periodontal disease
16 Unknown  Addition of Ezetimibe (Ezetrol®) to Ongoing Therapy With Rosuvastatin (Crestor®) in HIV Positive Patients Not Reaching Cholesterol Targets
Conditions: Hypercholesterolemia;   HIV Infections
Interventions: Drug: Ezetimibe;   Drug: Rosuvastatin (standard care)
Outcome Measures: The primary endpoint is the difference in final value of serum apolipoprotein B between participants treated with rosuvastatin versus participants treated with both rosuvastatin and ezetimibe.;   Percent change in apolipoprotein B, percent and absolute change total cholesterol, LDL, HDL, triglycerides, apolipoprotein A1, apolipoproteinB/apoliporoteinA1 ratio and C-reactive protein;   Assessment of safety parameters, specifically incidence of complications as measured by an increase in AST &/or ALT ≥3-fold ULN & a CK ≥10-fold ULN
17 Recruiting Brief Title:Effect of a Preoperative Calorie Restriction on Renal Function After Cardiac Surgery
Condition: Acute Renal Failure
Intervention: Other: calorie restriction
Outcome Measures: The Increase of serum creatinine in mg/dl 24 h after induction of ischemia ("cross clamping") in comparison to baseline value obtained in the morning of the day of surgery (day 0).;   Urine Neutrophil-Gelatinase associated Lipocalin (NGAL in µg/l) 8h after induction of ischemia in comparison to baseline value obtained in the morning of the day of surgery (day 0).;   C-reactive Protein (CRP) 24h after induction of ischemia;   Leucocyte count 24h after induction of ischemia;   Creatinkinase (CK) 24h after induction of ischemia;   Troponin T 24h after induction of ischemia;   Lactate dehydrogenase 24h after induction of ischemia;   N-terminal pro brain natriuretic peptide (NT-ProBNP) 24h after induction of ischemia;   Serum lactate 24h after induction of ischemia;   Maximum increase of serum creatinine within the first 48 h after induction of ischemia;   Necessity of renal replacement therapy during hospital stay;   In-hospital mortality;   Time until fit for discharge;   Length of hospital stay;   Echocardiographic estimated left-ventricular ejection fraction as per file, if assessed postoperatively;   Occurrence of acute renal failure in accordance with KDIGO I, II, III
18 Unknown  Effects of a Reduction in Kidney Function on Cardiovascular Structure and Function: A Prospective Study of Kidney Donors
Condition: Chronic Kidney Disease
Intervention:
Outcome Measures: Left ventricular mass as measured by CMR and Echocardiography;   Arterial stiffness as measured by pulse wave velocity;   Aortic compliance measured by cardiac magnetic resonance imaging;   Left ventricular systolic and diastolic elastance measured by echocardiography;;   Oxidative stress, inflammation and collagen turnover measured by blood assays of plasma renin, aldosterone, high sensitivity C-reactive protein (hsCRP), procollagen type III aminoterminal peptide (PIIINP) and C-telopeptide for type I collagen (CITP).
19 Unknown  The ACT-OUT Trial: ACTivity OUTcomes Based on High Carbohydrate or High Fat Diet in Metabolic Syndrome
Condition: Metabolic Syndrome
Intervention: Other: Low carbohydrate diet
Outcome Measures: changes in physical activity from baseline;   Change in lipids from baseline;   change in renal function from baseline
20 Recruiting Minocycline Augmentation to Clozapine
Conditions: Schizophrenia;   Schizoaffective Disorder
Intervention: Drug: Minocycline
Outcome Measures: Positive symptoms of schizophrenia/schizoaffective disorder;   Negative symptoms of schizophrenia/schizoaffective disorder;   Cognitive symptoms of schizophrenia/schizoaffective disorder;   Perceived quality of life and general well being;   Social, occupational, and psychological functioning;   Number of patients with adverse events;   Markers of inflammation, including C-Reactive Protein

These studies may lead to new treatments and are adding insight into C-reactive Protein Increased etiology and treatment.

A major focus of C-reactive Protein Increased research is the development of new drugs and other treatment options. Studies seek to identify new drugs to treat various related disorders and to find safer, more effective doses for medications already being used. Other research is aimed at identifying receptors or drug targets.


Discuss C-reactive Protein Increased